Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
INSMED Inc Chief Legal Officer Michael Alexander Smith reported an open-market sale of 4,109 shares of common stock at an average price of $116.18 per share. According to the filing, the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Following this tax-related sale, Smith directly holds 47,762 shares of INSMED common stock.
SHAROKY MELVIN MD reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director Melvin Sharoky received 3,305 Restricted Stock Units (RSUs) of Common Stock as a grant. The RSUs were granted on May 13, 2026 for no cash consideration and vest in full on the first anniversary of the grant date, subject to continued Board service and meeting-attendance conditions.
After this grant, Sharoky directly holds 246,081 shares of Common Stock, in addition to several indirect holdings through custodial UTMA/FL accounts, an LLC, and his spouse.
Brennan David R reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director David R. Brennan reported new equity compensation and existing indirect holdings. He received 3,305 Restricted Stock Units (RSUs), each representing one share of common stock, granted on May 13, 2026 for no consideration. These RSUs vest in full on the first anniversary of the grant date if he remains on the Board and attends at least 75% of Board meetings during the vesting period. After the grant, he directly holds 64,238 shares of common stock and has an additional 60,000 shares held indirectly through his spouse’s revocable trust.
Desjardins Clarissa reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director Clarissa Desjardins reported a new equity award and updated holdings. She received a grant of 3,305 Restricted Stock Units (RSUs) of Common Stock on May 13, 2026 for no cash consideration. After this grant, she holds 70,312 shares of Common Stock directly and 3,025 shares indirectly through her spouse.
The RSUs represent a contingent right to receive one share of Common Stock each and vest in full on the first anniversary of the grant date. Vesting requires that she remain on the Board through the earlier of that anniversary or the company’s annual shareholder meeting in that year and attend at least 75% of Board meetings during the vesting period.
LEE LEO reported acquisition or exercise transactions in this Form 4 filing.
Insmed Inc director Leo Lee reported receiving a grant of 3,305 shares of Common Stock in the form of Restricted Stock Units (RSUs) on May 13, 2026 for no cash consideration. Each RSU represents a contingent right to one share and vests in full on the first anniversary of the grant date if he remains on the Board through the earlier of that date or the company’s Annual Shareholder Meeting in that year, and attends at least 75% of Board meetings during the period. After this grant and an 11‑share downward correction for a prior clerical error, Lee beneficially owns 57,971 shares directly.
INSMED Inc Chair and CEO William Lewis reported an insider transaction involving company Common Stock. On May 13, 2026, he sold 13,283 shares at $116.18 per share, with a footnote explaining the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and related broker fees.
Following this sale, Lewis held 287,902 shares of Common Stock directly and 233,924 shares indirectly through a trust, indicating he retains a substantial equity stake in INSMED after these tax-related transactions.
Insmed Incorporated reported results from its annual shareholder meeting held on May 13, 2026. Shareholders elected Elizabeth McKee Anderson and Clarissa Desjardins, Ph.D., as Class II directors to serve until the 2029 annual meeting. Anderson received 153,734,471 votes for and 32,130,980 withheld, while Desjardins received 164,437,828 votes for and 21,427,623 withheld; each had 11,564,082 broker non-votes.
Shareholders also approved, on an advisory and non-binding basis, the 2025 compensation of the company’s named executive officers, with 162,133,728 votes for, 23,657,325 against, 74,398 abstentions and 11,564,082 broker non-votes. In addition, shareholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, by 190,386,612 votes for, 6,997,613 against and 45,308 abstentions.
INSMED Inc officer Martina Flammer reported a planned sale of 10,479 common shares, with an aggregate market value of $1,231,599 and an approximate sale date of May 14, 2026. The notice lists a Rule 10b5-1 plan adoption date of February 27, 2025. It also reports two earlier sales during the past three months: 12,949 shares for gross proceeds of $1,300,105 on May 11, 2026, and 7,854 shares for gross proceeds of $897,137 on May 13, 2026.
INSMED Inc officer Roger Adsett gave notice of a planned sale of 5,837 common shares, with an aggregate market value of $678,142 and an approximate sale date of May 13, 2026. Adsett acquired 5,837 shares through stock plan activity from the issuer on May 11, 2026. He also sold 88,060 shares on April 1, 2026, for gross proceeds of $14,497,473.
INSMED Inc officer Michael Smith reported a proposed sale of 4,109 common shares, with an aggregate market value of $477,383 and an approximate sale date of May 13, 2026. He acquired the shares from the issuer through stock plan activity on May 11, 2026. The listed prior sales were 19,638 shares on March 30, 2026, for gross proceeds of $2,964,929, and 24,774 shares on February 24, 2026, for gross proceeds of $3,859,153.